Importantly, even subclinical depression and/or anxiety at the baseline, greatly increases the chances for the development of depression during treatment with IFN-α (Van Thiel et al. 1998; Capuron and Ravaud 1999; Fontana et al. 2002; Hauser et al. 2002; Dieperink et al. 2003; Capuron and Miller 2004). Here, IFNA1 is linked to depressive symptom measurement.